

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Product (Standard Nucleic Acid, Micro-Scale Nucleic Acid, Large-Scale Nucleic Acid, Custom Nucleic Acid, Modified Nucleic Acid, Primers, Probes, Other Nucleic Acid, Other Services), By Chemical Synthesis (Solid-Phase Oligonucleotide Synthesis, Liquid-Phase Oligonucleotide Synthesis), By Technology (Column-Based Method, Microarray-Based Method), By End-User (Pharmaceutical Companies, Academic Research Institute, Diagnostic Laboratories) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-05-30 | 0 pages | Straits Research

AVAILABLE LICENSES:

- Single User License \$4500.00
- Global Site License \$5500.00

Report description:

Nucleic Acid Therapeutics CDMO Market Analysis and Insights

The Nucleic Acid Therapeutics CDMO Market size is anticipated to reach USD 1,908.41 Million in 2022 and it is projected to reach USD 4917.52 Million by 2031, growing at a CAGR of % during the forecast period.

The Global Nucleic Acid Therapeutics CDMO Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Nucleic Acid Therapeutics CDMO Market growth, Size report provides a comprehensive analysis of the Pharmaceuticals industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Nucleic Acid Therapeutics CDMO Market includes major suppliers & Independent Consultants among others. Global Market Scope and Nucleic Acid Therapeutics CDMO Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Nucleic Acid Therapeutics CDMO Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Nucleic Acid Therapeutics CDMO Market Country Level Analysis

The Global Nucleic Acid Therapeutics CDMO Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Nucleic Acid Therapeutics CDMO Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

Top Players in Nucleic Acid Therapeutics CDMO Market

Some of the other major highlights of the demand for Nucleic Acid Therapeutics CDMO Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Nucleic Acid Therapeutics CDMO Market during the forecast period.

Bachem Holding AG

Biospring GmbH

Danaher Corporation

Guangzhou Ruibo Biotechnology Co.Ltd.

LGC Limited

Merck KGaA

Nippon Shokubai Co.Ltd.

QIAGEN N.V.

ST Pharm Co Ltd

Nitto Denko Avecia Inc.

Sumitomo Chemical Co.Ltd.

Thermo Fisher Scientific Inc.

Wuxi AppTec

Syngene International Limited

Market Segmentation

The Global Nucleic Acid Therapeutics CDMO Market Share, Demand provides the most up-to-date Pharmaceuticals industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

By Product

Standard Nucleic Acid

Micro-Scale Nucleic Acid

Large-Scale Nucleic Acid

Custom Nucleic Acid

Modified Nucleic Acid

Primers

Probes

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Other Nucleic Acid
Other Services

By Chemical Synthesis

Solid-Phase Oligonucleotide Synthesis
Liquid-Phase Oligonucleotide Synthesis

By Technology

Column-Based Method
Microarray-Based Method

By End-User

Pharmaceutical Companies
Academic Research Institute
Diagnostic Laboratories

Regions Coverd

North America

U.S.
Canada

Europe

U.K.
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC

Scotts International. EU Vat number: PL 6772247784
tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com

China
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa

UAE
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM

Brazil
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents:

- 1 Executive Summary
- 2 Research Scope & Segmentation
 - 2.1 Research Objectives
 - 2.2 Limitations & Assumptions
 - 2.3 Market Scope & Segmentation
 - 2.4 Currency & Pricing Considered

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3 Market Opportunity Assessment
 - 3.1 Emerging Regions / Countries
 - 3.2 Emerging Companies
 - 3.3 Emerging Applications / End Use
- 4 Market Trends
 - 4.1 Drivers
 - 4.2 Market Warning Factors
 - 4.3 Latest Macro Economic Indicators
 - 4.4 Geopolitical Impact
 - 4.5 Technology Factors
- 5 Market Assessment
 - 5.1 Porters Five Forces Analysis
 - 5.2 Value Chain Analysis
- 6 Global Nucleic Acid Therapeutics CDMO Market Size Analysis
 - 6.1 By Product
 - 6.1.1 Standard Nucleic Acid
 - 6.1.2 Micro-Scale Nucleic Acid
 - 6.1.3 Large-Scale Nucleic Acid
 - 6.1.4 Custom Nucleic Acid
 - 6.1.5 Modified Nucleic Acid
 - 6.1.6 Primers
 - 6.1.7 Probes
 - 6.1.8 Other Nucleic Acid
 - 6.1.9 Other Services
 - 6.2 By Chemical Synthesis
 - 6.2.1 Solid-Phase Oligonucleotide Synthesis
 - 6.2.2 Liquid-Phase Oligonucleotide Synthesis
 - 6.3 By Technology
 - 6.3.1 Column-Based Method
 - 6.3.2 Microarray-Based Method
 - 6.4 By End-User
 - 6.4.1 Pharmaceutical Companies
 - 6.4.2 Academic Research Institute
 - 6.4.3 Diagnostic Laboratories
- 7 North America Market Analysis
 - 7.1 By Product
 - 7.1.1 Standard Nucleic Acid
 - 7.1.2 Micro-Scale Nucleic Acid
 - 7.1.3 Large-Scale Nucleic Acid
 - 7.1.4 Custom Nucleic Acid
 - 7.1.5 Modified Nucleic Acid
 - 7.1.6 Primers
 - 7.1.7 Probes
 - 7.1.8 Other Nucleic Acid
 - 7.1.9 Other Services
 - 7.2 By Chemical Synthesis
 - 7.2.1 Solid-Phase Oligonucleotide Synthesis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.2.2 Liquid-Phase Oligonucleotide Synthesis
- 7.3 By Technology
 - 7.3.1 Column-Based Method
 - 7.3.2 Microarray-Based Method
- 7.4 By End-User
 - 7.4.1 Pharmaceutical Companies
 - 7.4.2 Academic Research Institute
 - 7.4.3 Diagnostic Laboratories
- 7.4 U.S.
- 7.5 Canada
- 8 Europe Market Analysis
 - 8.1 By Product
 - 8.1.1 Standard Nucleic Acid
 - 8.1.2 Micro-Scale Nucleic Acid
 - 8.1.3 Large-Scale Nucleic Acid
 - 8.1.4 Custom Nucleic Acid
 - 8.1.5 Modified Nucleic Acid
 - 8.1.6 Primers
 - 8.1.7 Probes
 - 8.1.8 Other Nucleic Acid
 - 8.1.9 Other Services
 - 8.2 By Chemical Synthesis
 - 8.2.1 Solid-Phase Oligonucleotide Synthesis
 - 8.2.2 Liquid-Phase Oligonucleotide Synthesis
 - 8.3 By Technology
 - 8.3.1 Column-Based Method
 - 8.3.2 Microarray-Based Method
 - 8.4 By End-User
 - 8.4.1 Pharmaceutical Companies
 - 8.4.2 Academic Research Institute
 - 8.4.3 Diagnostic Laboratories
 - 8.4 U.K.
 - 8.5 Germany
 - 8.6 France
 - 8.7 Spain
 - 8.8 Italy
 - 8.9 Russia
 - 8.10 Nordic
 - 8.11 Benelux
 - 8.12 Rest of Europe
- 9 APAC Market Analysis
 - 9.1 By Product
 - 9.1.1 Standard Nucleic Acid
 - 9.1.2 Micro-Scale Nucleic Acid
 - 9.1.3 Large-Scale Nucleic Acid
 - 9.1.4 Custom Nucleic Acid
 - 9.1.5 Modified Nucleic Acid

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.1.6 Primers
- 9.1.7 Probes
- 9.1.8 Other Nucleic Acid
- 9.1.9 Other Services
- 9.2 By Chemical Synthesis
 - 9.2.1 Solid-Phase Oligonucleotide Synthesis
 - 9.2.2 Liquid-Phase Oligonucleotide Synthesis
- 9.3 By Technology
 - 9.3.1 Column-Based Method
 - 9.3.2 Microarray-Based Method
- 9.4 By End-User
 - 9.4.1 Pharmaceutical Companies
 - 9.4.2 Academic Research Institute
 - 9.4.3 Diagnostic Laboratories
- 9.4 China
- 9.5 Korea
- 9.6 Japan
- 9.7 India
- 9.8 Australia
- 9.9 Taiwan
- 9.10 South East Asia
- 9.11 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
 - 10.1 By Product
 - 10.1.1 Standard Nucleic Acid
 - 10.1.2 Micro-Scale Nucleic Acid
 - 10.1.3 Large-Scale Nucleic Acid
 - 10.1.4 Custom Nucleic Acid
 - 10.1.5 Modified Nucleic Acid
 - 10.1.6 Primers
 - 10.1.7 Probes
 - 10.1.8 Other Nucleic Acid
 - 10.1.9 Other Services
 - 10.2 By Chemical Synthesis
 - 10.2.1 Solid-Phase Oligonucleotide Synthesis
 - 10.2.2 Liquid-Phase Oligonucleotide Synthesis
 - 10.3 By Technology
 - 10.3.1 Column-Based Method
 - 10.3.2 Microarray-Based Method
 - 10.4 By End-User
 - 10.4.1 Pharmaceutical Companies
 - 10.4.2 Academic Research Institute
 - 10.4.3 Diagnostic Laboratories
 - 10.4 UAE
 - 10.5 Turkey
 - 10.6 Saudi Arabia
 - 10.7 South Africa

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.8 Egypt
- 10.9 Nigeria
- 10.10 Rest of MEA
- 11 LATAM Market Analysis
 - 11.1 By Product
 - 11.1.1 Standard Nucleic Acid
 - 11.1.2 Micro-Scale Nucleic Acid
 - 11.1.3 Large-Scale Nucleic Acid
 - 11.1.4 Custom Nucleic Acid
 - 11.1.5 Modified Nucleic Acid
 - 11.1.6 Primers
 - 11.1.7 Probes
 - 11.1.8 Other Nucleic Acid
 - 11.1.9 Other Services
 - 11.2 By Chemical Synthesis
 - 11.2.1 Solid-Phase Oligonucleotide Synthesis
 - 11.2.2 Liquid-Phase Oligonucleotide Synthesis
 - 11.3 By Technology
 - 11.3.1 Column-Based Method
 - 11.3.2 Microarray-Based Method
 - 11.4 By End-User
 - 11.4.1 Pharmaceutical Companies
 - 11.4.2 Academic Research Institute
 - 11.4.3 Diagnostic Laboratories
 - 11.4 Brazil
 - 11.5 Mexico
 - 11.6 Argentina
 - 11.7 Chile
 - 11.8 Colombia
 - 11.9 Rest of LATAM
- 12 Competitive Landscape
 - 12.1 Global Nucleic Acid Therapeutics CDMO Market Share By Players
 - 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
 - 13.1 American International Industries (GIGI)
 - 13.1.1 Overview
 - 13.1.2 Business Information
 - 13.1.3 Revenue
 - 13.1.4 ASP
 - 13.1.5 Swot Analysis
 - 13.1.6 Recent Developments
 - 13.2 Biospring GmbH
 - 13.3 Danaher Corporation
 - 13.4 Guangzhou Ruibo Biotechnology Co.Ltd.
 - 13.5 LGC Limited
 - 13.6 Merck KGaA
 - 13.7 Nippon Shokubai Co.Ltd.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.8 QIAGEN N.V.
- 13.9 ST Pharm Co Ltd
- 13.10 Nitto Denko Avecia Inc.
- 13.11 Sumitomo Chemical Co.Ltd.
- 13.12 Thermo Fisher Scientific Inc.
- 13.13 Wuxi AppTec
- 13.14 Syngene International Limited
- 14 Research Methodology
 - 14.1 Research Data
 - 14.1.1 Secondary Data
 - 14.1.1.1 Major secondary sources
 - 14.1.1.2 Key data from secondary sources
 - 14.1.2 Primary Data
 - 14.1.2.1 Key data from primary sources
 - 14.1.2.2 Breakdown of primaries
 - 14.1.3 Secondary And Primary Research
 - 14.1.3.1 Key industry insights
 - 14.2 Market Size Estimation
 - 14.2.1 Bottom-Up Approach
 - 14.2.2 Top-Down Approach
 - 14.2.3 Market Projection
 - 14.3 Research Assumptions
 - 14.3.1 Assumptions
 - 14.4 Limitations
 - 14.5 Risk Assessment
- 15 Appendix
 - 15.1 Discussion Guide
 - 15.2 Customization Options
 - 15.3 Related Reports
- 16 Disclaimer

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Product (Standard Nucleic Acid, Micro-Scale Nucleic Acid, Large-Scale Nucleic Acid, Custom Nucleic Acid, Modified Nucleic Acid, Primers, Probes, Other Nucleic Acid, Other Services), By Chemical Synthesis (Solid-Phase Oligonucleotide Synthesis, Liquid-Phase Oligonucleotide Synthesis), By Technology (Column-Based Method, Microarray-Based Method), By End-User (Pharmaceutical Companies, Academic Research Institute, Diagnostic Laboratories) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-05-30 | 0 pages | Straits Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Global Site License	\$5500.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*

Phone*

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	
		Date	2026-02-23
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com